Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 15
Treatment-assignment count: 0
Stratification count: 0
Drug Development Ahead Of Cdx Context
MET exon 14 skipping
melanoma · Small Molecule Inhibitor
MET exon 14 skipping is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 16 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT01120275 | https://clinicaltrials.gov/study/NCT02314143 | https://clinicaltrials.gov/study/NCT01902173 | https://clinicaltrials.gov/study/NCT01979523 | https://clinicaltrials.gov/study/NCT01480154 | https://clinicaltrials.gov/study/NCT01835184 | https://clinicaltrials.gov/study/NCT01519427 | https://clinicaltrials.gov/study/NCT03425461 | https://clinicaltrials.gov/study/NCT01072175 | https://clinicaltrials.gov/study/NCT02369029 | https://clinicaltrials.gov/study/NCT03637803 | https://clinicaltrials.gov/study/NCT02723006 | https://clinicaltrials.gov/study/NCT02645149 | https://clinicaltrials.gov/study/NCT03008018 | https://clinicaltrials.gov/study/NCT03958383 | https://clinicaltrials.gov/study/NCT04253080